Microbead-based technologies in diagnostic autoantibody detection

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 1, 2009, Pages 81-89

  Fritzler, Marvin J ^a   Fritzler, Mark L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Addressable laser bead; Autoantibodies; Diagnostic assays; Luminex

Indexed keywords

ANTIBODY DETECTION; CLINICAL LABORATORY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; IMMUNOASSAY; LASER; MAGNETISM; MICROBEAD IMMUNOASSAY; REVIEW;

EID: 77953433878     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050802651561     Document Type: Review

References (72)

1. Wassermann VA, Neisser A, Bruck C. Eine serodiagnostische reaktion bei syphilis. Dtsch Med Wochenschr 1906;19:745-746
2. McHugh NJ, Distler O, Giacomelli R, Riemekasten G. Non organ based laboratory markers in systemic sclerosis. Clin Exp Rheumatol 2003;21:S32-8 (Pubitemid 41116909)
3. Moore JE, Lutz WB. The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false-positive reactors. J Chronic Dis 1955;1:297-316
4. Harvey AM, Shulman LE. Connective tissue disease and the chronic biologic false positive test for syphyllis (BFP-STS reaction). Med Clin North Am 1966;50:1271-1279
5. Koike T, Sueishi M, Funaki H, et al. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984;56:193-199 (Pubitemid 14161205)
6. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the "tart" cells and the "L.E." cell. Mayo Clin Proc 1948;27:25-28
7. Hamburger RN. Induction of the lupus erythematosus ("L.E.") cell in vitro in peripheral blood. Yale J Biol Med 1950;22:407-410
8. Conn RB. Practice parameter - the lupus erythematosus cell test. Am J Clin Pathol 1994;101:65-66
9. Fritzler MJ, Wiik A. Autoantibody Assays, Testing, and Standardization. In: Rose NR, Mackay IR, editors, The Autoimmune Diseases. Sydney: Elsevier Academic Press; 2006;p. 1011-1022
10. Tozzoli R. Recent advances in diagnostic technologies and their impact in autoimmune diseases. Autoimmun Rev 2007;6:334-340 (Pubitemid 46810401)
11. Wiik AS, Gordon TP, Kavanaugh AF, et al. Cutting edge diagnostics in rheumatology: on the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Care Res 2004;51:291-298 (Pubitemid 38468717)
12. Hendrick JP, Wolin SL, Rinke J, et al. Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. Mol Cell Biol 1981;1:1138-1148 (Pubitemid 12178359)
13. Harmon CE, Deng JS, Peebles CL, Tan EM. The importance of tissue substrate in the SS-ARo antigen-antibody system. Arthritis Rheum 1984;27:166-173 (Pubitemid 14191021)
14. Miyachi K, Hirano Y, Horigome T, et al. Autoantibodies from primary biliary cirrhosis patients with anti-p95c antibodies bind to recombinant p97/VCP and inhibit in vitro nuclear envelope assembly. Clin Exp Immunol 2004;136:568-573 (Pubitemid 38703694)
15. Fritzler MJ. Autoantibody testing: procedures and significance in systemic rheumatic diseases. Meth Achiev Exp Pathol 1986;12:224-260
16. Enarson P, Rattner JB, Ou Y, et al. Autoantigens of the nuclear pore complex. J Mol Med 2004;82:423-433 (Pubitemid 39044282)
17. Fritzler MJ. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 2006;15:422-427 (Pubitemid 44147087)
18. Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases? Arthritis Rheum 2007;56:1736-1744
19. Wiik A, Fritzler MJ. Laboratory Tests in Rheumatic Disorders. In: Hochberg M, Silman A, Smolen J, et al., editors, Rheumatology. Philadelphia: Mosby; 2008;p. 219-232
20. Fritzler MJ. Advances in understanding newer autoantibodies and their role as biomarkers in systemic lupus erythematosus. Expert Opin Med Diagn 2007;1:393-408
21. Craft J, Hardin JA. Linked sets of antinuclear antibodies: what do they mean? J Rheumatol 1987;14(Suppl):106-109
22. Theofilopoulos AN. The basis of autoimmunity: Part I Mechanisms of abberant self-recognition. Immunol Today 1995;16:90-98
23. Deshmukh US, Gaskin F, Lewis JE, et al. Mechanisms of autoantibody diversification to SLE-related autoantigens. Ann NY Acad Sci 2003;987:91-98
24. Harley JB, James JA. Autoepitopes in lupus. J Lab Clin Med 1995;126:509-516 (Pubitemid 3019063)
25. Monneaux F, Muller S. Epitope spreading in systemic lupus erythematosus - identification of triggering peptide sequences. Arthritis Rheum 2002;46:1430-1438
26. Deshmukh US, Bagavant H, Lewis J, et al. Epitope spreading within lupus-associated ribonucleoprotein antigens. Clin Immunol 2005;117:112-120 (Pubitemid 41407720)
27. Nakamura RM, Tan EM. Autoantibodies to nonhistone nuclear antigens and their clinical significance. Hum Pathol 1983;14:392-400
28. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005;84:231-249 (Pubitemid 41026298)
29. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus. Semin Arthritis Rheum 2004;34:501-537
30. Sherer Y, Shoenfeld Y. Autoantibody explosion in lupus - 155 different autoantibodies in SLE. Lupus 2007;16(Suppl):42
31. Fritzler MJ. Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun Rev 2008;7:616-620
32. Tozzoli R. Review: the diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases. Clin Chem Lab Med 2008;46:577-587
33. Ghavidel A, Cagney G, Emili A. A skeleton of the human protein interactome. Cell 2005;122:830-832 (Pubitemid 41345200)
34. Cusick ME, Klitgord N, Vidal M, Hill DE. Interactome: gateway into systems biology. Hum Mol Genet 2005;14(Spec No. 2): R171-81. [Epub;% 14 Sep 2005: R171-R181]
35. Shoenfeld Y, Toubi E. Protective autoantibodies: role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum 2005;52:2599-2606 (Pubitemid 41369087)
36. Meroni PL, Shoenfeld Y. Predictive, protective, orphan autoantibodies: The example of the anti-phospholipid antibodies. Autoimmun Rev 2008;7:585-587
37. Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 2008;4:491-498
38. Mahler M, Raijmakers R, Fritzler MJ. Challenges and controversies associated with systemic rheumatic diseases. Curr Rheumatol Rev 2007;3:67-78 (Pubitemid 46592818)
39. Mahler M, Fritzler MJ. Novel aspects of autoantibodies to the human exosome (PM/Scl complex). In: Conrad K, Chan EKL, Fritzler MJ, et al., editors, From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Lengerich, Germany: Pabst Science Publishers; 2007;p. 178-193
40. Griesmacher A, Peichl P. Autoantibodies associated with rheumatic diseases. Clin Chem Lab Med 2001;39:189-208 (Pubitemid 32396393)
41. Rattner JB, Whitehead C, Matyas J, et al. Autoantibodies to the cell cycle specific protein CENP-F are found in patients with maliganancy and distinguish G2-M populations in normal and neoplastic tissues. Clin Invest Med 1997;20:308-319
42. Rattner JB, Rees J, Whitehead CM, et al. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997;20:308-319 (Pubitemid 27472722)
43. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007;56:2344-2351 (Pubitemid 47173582)
44. Conrad K, Schlösser W, Fritzler MJ. The predictive relevance of autoantibodies. In: Conrad K, Chan EKL, Fritzler MJ, et al., editors, From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Langerich, Germany: Pabst Scientific Publishers; 2007;p. 16-31
45. Goldknopf IL. Molecular diagnostics and proteomics on the outskirts of personalized medicine. Expert Rev Mol Diagn 2007;7:339-343 (Pubitemid 47066549)
46. Allison M. Is personalized medicine finally arriving? Nat Biotechnol 2008;26:509-517
47. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004;50:1709-1720
48. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004;50:2048-2065
49. New directions in diagnostics. Med Device Technol 2000;11:33
50. Picard FJ, Bergeron MG. Rapid molecular theranostics in infectious diseases. Drug Discov Today 2002;7:1092-1101 (Pubitemid 35341650)
51. Hooper JW. The genetic map to theranostics. MLO Med Lab Obs 2006;38:22-25
52. Bissonnette L, Bergeron MG. Next revolution in the molecular theranostics of infectious diseases: microfabricated systems for personalized medicine. Expert Rev Mol Diagn 2006;6:433-450 (Pubitemid 44174347)
53. Chatterjee M, Draghici S, Tainsky MA. Immunotheranostics: breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays. Curr Opin Drug Discov Devel 2006;9:380-385
54. Fritzler MJ, Fritzler ML. The emergence of multiplexed technologies as diagnostic platforms in systemic autoimmune diseases. Curr Med Chem 2006;13:2503-2512 (Pubitemid 44364152)
55. Fritzler MJ. New technologies in the detection of autoantibodies: Evaluation of addressable laser bead immunoassays (ALBIA). In: Conrad K, Bachmann MP, Chan EKL, et al., editors, From animal models to human genetics: Research on the induction and pathogenicity of autoantibodies. Lengerich: Pabst Scientific Publishers; 2004;p. 449-462
56. Shovman O, Gilburd B, Barzilai O, et al. Evaluation of the BioPlexTM 2200 ANA Screen: Analysis of 510 Healthy Subjects: incidence of Natural/Predictive Autoantibodies. Ann NY Acad Sci 2005;1050:380-388 (Pubitemid 41129457)
57. Shovman O, Gilburd B, Zandman-Goddard G, et al. Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases. Autoimmun 2005;38:105-109 (Pubitemid 40515010)
58. Rouquette AM, Desgruelles C, Laroche P. Evaluation of the new multiplexed immunoassay, FIDIS, for simultaneous quantitative determination of antinuclear antibodies and comparison with conventional methods. Am J Clin Pathol 2003;120:676-681 (Pubitemid 37339673)
59. Gilburd B, bu-Shakra M, Shoenfeld Y, et al. Autoantibodies profile in the sera of patients with Sjogren's syndrome: the ANA evaluation - a homogeneous, multiplexed system. Clin Dev Immunol 2004;11:53-56
60. Pang S, Smith J, Onley D, et al. A comparability study of the emerging protein array platforms with established ELISA procedures. J Immunol Methods 2005;302:1-12 (Pubitemid 41111868)
61. Fritzler MJ, Behmanesh F, Fritzler ML. Analysis of human sera that are polyreactive in an addressable laser bead immunoassay. Clin Immunol 2006;120:349-356 (Pubitemid 44175894)
62. Fritzler MJ, Wiik A, Fritzler ML, Barr SG. The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 2003;5:192-201 (Pubitemid 36926686)
63. Bossuyt X, Louche C, Wiik A. Standardisation in clinical laboratory medicine: an ethical reflection. Ann Rheum Dis 2008;67:1061-1063
64. Graham KL, Vaysberg M, Kuo A, Utz PJ. Autoantigen arrays for multiplex analysis of antibody isotypes. Proteomics 2006;6:5720-5724 (Pubitemid 44764009)
65. Balboni I, Limb C, Tenenbaum JD, Utz PJ. Evaluation of microarray surfaces and arraying parameters for autoantibody profiling. Proteomics 2008;8:3443-3449
66. Chen Z, Tabakman SM, Goodwin AP, et al. Protein microarrays with carbon nanotubes as multicolor Raman labels. Nat Biotechnol 2008;26:1285-1292
67. Robinson WH, Steinman L, Utz PJ. Protein and peptide array analysis of autoimmune disease. BioTechniques 2002;(Suppl):66-69 (Pubitemid 36008166)
68. Venkatasubbarao S. Microarrays - status and prospects. Trends Biotechnol 2004;22:630-637 (Pubitemid 39473213)
69. Jain KK. Nanodiagnostics: application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn 2003;3:153-161 (Pubitemid 36313749)
70. Freeman RG, Raju PA, Norton SM, et al. Use of nanobarcodes particles in bioassays. Methods Mol Biol 2005;303:73-83
71. Kattah MG, Utz PJ, Balboni I. Protein microarrays address the elephant in the room. Clin Chem 2008;54:937-939 (Pubitemid 351793397)
72. Kniss R. Revolution of the drug discovery process using laboratory-on-a-chip technology. Am Lab 1998;30:40-42